Patient in Sarepta gene therapy trial develops serious illness; shares plunge

Shares of Sarepta Therapeutics Inc plunged 12% after a notice from the U.S. health agency showed a patient in an ongoing study of the company's gene therapy for Duchenne muscular dystrophy (DMD) was reported to have developed a serious illness.